duloxetine hydrochloride has been researched along with tapentadol in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badghisi, H; Meske, DS; Ossipov, MH; Oyarzo, J; Porreca, F; Xie, JY | 1 |
| Dickenson, AH | 1 |
| Bannister, K; Dickenson, AH; Goncalves, L; Patel, R; Townson, L | 1 |
| Gibbs, LM; Lindsay, TJ; Snyder, MJ | 1 |
1 review(s) available for duloxetine hydrochloride and tapentadol
| Article | Year |
|---|---|
Treating Painful Diabetic Peripheral Neuropathy: An Update.
Topics: Administration, Topical; Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anesthetics, Local; Capsaicin; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Duloxetine Hydrochloride; Gabapentin; gamma-Aminobutyric Acid; Humans; Isosorbide Dinitrate; Lidocaine; Phenols; Pregabalin; Selective Serotonin Reuptake Inhibitors; Sensory System Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Tapentadol; Tramadol; Transcutaneous Electric Nerve Stimulation; Vasodilator Agents; Venlafaxine Hydrochloride | 2016 |
3 other study(ies) available for duloxetine hydrochloride and tapentadol
| Article | Year |
|---|---|
Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain.
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Duloxetine Hydrochloride; Male; Morphine; Neuralgia; Norepinephrine; Pain Measurement; Phenols; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Spinal Nerves; Tapentadol; Thiophenes | 2014 |
Commentary on: Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain.
Topics: Analgesics, Opioid; Animals; Duloxetine Hydrochloride; Male; Morphine; Neuralgia; Phenols; Spinal Nerves; Tapentadol; Thiophenes | 2014 |
Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations.
Topics: Action Potentials; Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; Animals; Biogenic Monoamines; Diffuse Noxious Inhibitory Control; Disease Models, Animal; Duloxetine Hydrochloride; Evoked Potentials; Male; Neurons; Ondansetron; Peripheral Nerve Injuries; Phenols; Rats; Rats, Sprague-Dawley; Recovery of Function; Serotonin and Noradrenaline Reuptake Inhibitors; Serotonin Antagonists; Tapentadol; Time Factors; Yohimbine | 2015 |